Rabies Vaccine Market is estimated to increase at a Compounded Annual Growth Rate of 4.9% CAGR over the forecast period from 2024 to 2030
The Rabies Vaccine Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Chick embryo cells rabies vaccine, Vero cell rabies vaccine, Human diploid cell vaccine, Others), By Prophylaxis Type (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Application (Human, Animal), By End-User (Hospitals, Veterinary clinics, Others).
An Introduction to Rabies Vaccine Market in 2024
The market for rabies vaccines remains crucial in 2024, contributing to global efforts to eliminate rabies as a public health threat. Rabies, a viral zoonotic disease transmitted through the bite of infected animals, poses significant risks to human health, particularly in regions where canine rabies is endemic. Vaccination remains the cornerstone of rabies prevention, with both pre-exposure prophylaxis for individuals at high risk of exposure and post-exposure prophylaxis for those bitten by potentially rabid animals. The market offers a range of rabies vaccine formulations, including conventional inactivated vaccines and newer-generation recombinant vaccines, characterized by improved safety profiles and enhanced immunogenicity. Additionally, efforts to increase vaccine accessibility, promote community awareness, and implement animal control measures contribute to the market's growth and the global initiative to eliminate human rabies deaths by 2030.
Market Trend: Shift Towards Novel Vaccine Technologies
A significant trend in the rabies vaccine market is the shift towards novel vaccine technologies. Traditional rabies vaccines have relied on conventional methods such as inactivated virus or live attenuated virus vaccines. However, advancements in vaccine development, including recombinant DNA technology, virus-like particles (VLPs), and mRNA-based vaccines, are reshaping the landscape. These innovative approaches offer potential advantages such as improved safety profiles, enhanced immunogenicity, and scalability. Additionally, the emergence of new delivery platforms and adjuvants further contributes to the diversification of rabies vaccine options. This trend reflects a growing emphasis on innovation and the pursuit of more effective and accessible vaccines to combat rabies, particularly in regions where the disease remains endemic.
Market Driver: Rising Incidence of Rabies Cases and Increased Awareness
A primary driver fueling the rabies vaccine market is the rising incidence of rabies cases and increased awareness of the disease's public health impact. Despite being entirely preventable through vaccination, rabies continues to pose a significant threat to human and animal populations globally, particularly in regions with limited access to healthcare and vaccination programs. The growing recognition of the burden of rabies and its potential for fatal outcomes has led to heightened efforts to control and eliminate the disease through vaccination campaigns and public education initiatives. Furthermore, the expansion of international travel and trade heightens the risk of rabies transmission, driving the demand for pre-exposure and post-exposure prophylaxis. This heightened awareness, coupled with proactive measures to address the disease, serves as a key driver for the growth of the rabies vaccine market.
Market Opportunity: Expansion into Emerging Markets and Veterinary Vaccines
An opportunity within the rabies vaccine market lies in the expansion into emerging markets and the development of veterinary vaccines. While rabies predominantly affects regions with limited resources and infrastructure, there is a growing demand for affordable and accessible vaccines in these areas. Expanding market penetration into emerging economies presents a significant opportunity for vaccine manufacturers to address unmet needs and contribute to rabies control efforts on a global scale. Additionally, the veterinary segment offers untapped potential, as rabies remains a threat to animal populations worldwide. By developing vaccines tailored to the needs of companion animals, livestock, and wildlife, companies can not only safeguard animal health but also contribute to the prevention of rabies transmission to humans. This dual approach to market expansion underscores the broader public health impact of rabies vaccination and represents a promising opportunity for growth and innovation within the rabies vaccine market.
Rabies Vaccine Market Share Analysis: Vero Cell Rabies Vaccine
In the Rabies Vaccine Market, the segment related to Vero cell rabies vaccine shows significant growth potential. Vero cell vaccines are produced using African green monkey kidney cells (Vero cells) as the substrate for propagating the rabies virus. This technology offers several advantages, including enhanced safety, reduced risk of residual cellular DNA, and minimal risk of allergic reactions compared to traditional vaccines produced in animal-derived substrates. Vero cell rabies vaccines are widely used for both pre-exposure prophylaxis and post-exposure prophylaxis in both human and animal populations. The increasing awareness of rabies prevention, coupled with rising pet ownership and growing concerns about wildlife rabies transmission, drives the demand for effective and safe rabies vaccines. Hospitals and veterinary clinics serve as crucial distribution channels for administering rabies vaccines to individuals and animals, further fueling the market growth for Vero cell rabies vaccines. As countries implement vaccination programs and enhance surveillance and control measures against rabies, the demand for Vero cell rabies vaccines is expected to surge, presenting lucrative opportunities for manufacturers and suppliers operating in this segment.
Rabies Vaccine Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBerna Biotech Ltd, Bharat Biotech International Ltd, Boehringer Ingelheim International GmbH, Elanco Animal Health, GlaxoSmithKline plc, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Virbac Corp, Zoetis Inc
Rabies Vaccine Market Segmentation
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Rabies Vaccine Market Companies
Berna Biotech Ltd
Bharat Biotech International Ltd
Boehringer Ingelheim International GmbH
Elanco Animal Health
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Virbac Corp
Zoetis Inc
Reasons to Buy the Rabies Vaccine Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Rabies Vaccine Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Rabies Vaccine Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Rabies Vaccine Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Rabies Vaccine Market Size Outlook, $ Million, 2021 to 2030
3.2 Rabies Vaccine Market Outlook by Type, $ Million, 2021 to 2030
3.3 Rabies Vaccine Market Outlook by Product, $ Million, 2021 to 2030
3.4 Rabies Vaccine Market Outlook by Application, $ Million, 2021 to 2030
3.5 Rabies Vaccine Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Rabies Vaccine Industry
4.2 Key Market Trends in Rabies Vaccine Industry
4.3 Potential Opportunities in Rabies Vaccine Industry
4.4 Key Challenges in Rabies Vaccine Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Rabies Vaccine Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Rabies Vaccine Market Outlook by Segments
7.1 Rabies Vaccine Market Outlook by Segments, $ Million, 2021- 2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
8 North America Rabies Vaccine Market Analysis and Outlook To 2030
8.1 Introduction to North America Rabies Vaccine Markets in 2024
8.2 North America Rabies Vaccine Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Rabies Vaccine Market size Outlook by Segments, 2021-2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
9 Europe Rabies Vaccine Market Analysis and Outlook To 2030
9.1 Introduction to Europe Rabies Vaccine Markets in 2024
9.2 Europe Rabies Vaccine Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Rabies Vaccine Market Size Outlook by Segments, 2021-2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
10 Asia Pacific Rabies Vaccine Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Rabies Vaccine Markets in 2024
10.2 Asia Pacific Rabies Vaccine Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Rabies Vaccine Market size Outlook by Segments, 2021-2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
11 South America Rabies Vaccine Market Analysis and Outlook To 2030
11.1 Introduction to South America Rabies Vaccine Markets in 2024
11.2 South America Rabies Vaccine Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Rabies Vaccine Market size Outlook by Segments, 2021-2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
12 Middle East and Africa Rabies Vaccine Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Rabies Vaccine Markets in 2024
12.2 Middle East and Africa Rabies Vaccine Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Rabies Vaccine Market size Outlook by Segments, 2021-2030
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Berna Biotech Ltd
Bharat Biotech International Ltd
Boehringer Ingelheim International GmbH
Elanco Animal Health
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Virbac Corp
Zoetis Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others
By Prophylaxis Type
Pre-exposure prophylaxis
Post-exposure prophylaxis
By Application
Human
Animal
By End-User
Hospitals
Veterinary clinics
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
